Global Neglected Tropical Disease Market, By Disease (Dengue, Rabies, Trachoma, Buruli Ulcer, Yaws, Leprosy, Chagas Disease, Human African Trypanosomiasis, Leishmaniases, Soil-Transmitted Helminthiases, Others) Product (Drugs, Vaccines) – Industry Tr
ends and Forecast to 2029.
Market Analysis and Size
In recent years factors including a lack of basic services such as clean water, a lack of proper hygiene maintenance, and a lack of steps to prevent such diseases, have contributed to an increase in the prevalence of neglected tropical diseases in recent years. In the coming years, this situation is expected to create significant sales opportunities for companies operating in the global neglected tropical disease market.
Data Bridge Market Research analyses that the neglected tropical disease market is expected to reach the value of USD 2.04 billion by the year 2029, at a CAGR of 5.75% during the forecast period. The growing number of programs aimed at combating NTDs is expected to open up new opportunities for the market.
Market Definition
Neglected tropical diseases (NTDs) are a diverse group of communicable diseases that occur in tropical and subtropical environments in 149 countries, affecting over one billion people and costing developing economies billions of dollars each year. NTDs such as dengue fever, lymphatic filariasis, Chagas, trachoma, and leishmaniasis are referred to as neglected because they primarily affect the poor and have historically received less attention than other diseases. NTDs thrive in developing regions of the world with poor water quality, sanitation, and access to healthcare.
Neglected Tropical Disease Market Dynamics
Drivers
- The rise in the NTD cases in tropical and subtropical countries
Increased government initiative, increased awareness about NTDs, and an increase in NTD cases in tropical and subtropical countries are expected to drive market growth during the forecast period. There is also an increase in cases of Buruli ulcers and dengue fever around the world, which will accelerate the growth of the neglected tropical disease market.
- Government intervention in rising awareness about neglected tropical diseases
Government organisations in major countries around the world are taking steps to raise awareness about neglected tropical diseases and increase the availability of medicines used to treat these diseases. An increase in the number of such initiatives is expected to boost growth prospects in the global neglected tropical disease market in the coming years.
- Regulatory Compliance
Maintaining compliance with medical reforms and regulations raises the demand for these solutions.
Opportunities
Major players in the global market for neglected tropical diseases are increasing their financial and time investments in R&D activities. This strategy is assisting them in the development of new and more effective drugs for the treatment of neglected tropical diseases.
This neglected tropical disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Neglected Tropical Disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- The World Health Organization (WHO) is attempting to raise awareness about one of the most underappreciated tropical diseases, Buruli ulcer. It has launched the Global Buruli Ulcer Initiative to raise awareness of the condition.
- The UN Development Programme (UNDP) and various organisations launched the Uniting Efforts for Innovation, Access, and Delivery initiative in January 2019 to improve access to medicines, diagnostics, and vaccines for neglected tropical diseases. Over the forecast period, many such initiatives are expected to increase the consumption of neglected tropical disease treatment drugs. Stop Dengue mission in India, which aims to reduce morbidity and mortality rates due to dengue in the country by raising awareness about better hygiene practises.
Global Neglected Tropical Disease Market Scope
The neglected tropical disease market is segmented on the basis of disease and product. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Dengue
- Rabies
- Trachoma
- Buruli Ulcer
- Yaws
- Leprosy
- Chagas Disease
- Human African Trypanosomiasis
- Leishmaniases
- Soil-Transmitted Helminthiases
- Others
On the basis of disease, the neglected tropical disease market is segmented into dengue, rabies, trachoma, buruli ulcer, yaws, leprosy, chagas disease, human african trypanosomiasis, leishmaniases, soil-transmitted helminthiases and others.
Product
- Drugs
- Vaccines
Based on product, the neglected tropical disease market is segmented into drugs and vaccines.
Neglected Tropical Disease Market Regional Analysis/Insights
The neglected tropical disease market is analysed and market size insights and trends are provided by country, disease and product as referenced above.
The countries covered in the neglected tropical disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is likely to maintain its lead. The primary factor influencing demand here is the increasing inflow of transient population from developed to developing countries. Furthermore, Europe will continue to be a significant player in the global neglected tropical disease treatment. However, it is expected that Asia Pacific will develop as a strategic region. Improving healthcare, government pressure to reduce NTDs, and increasing individual awareness will boost demand in this sector..
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The neglected tropical disease market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Neglected Tropical Disease market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Neglected Tropical Disease market. The data is available for historic period 2010-2020.
Competitive Landscape and Neglected Tropical Disease Market Share Analysis
The neglected tropical disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Neglected Tropical Disease market.
Some of the major players operating in the neglected tropical disease market are GlaxoSmithKline plc., Bayer AG, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Astellas Pharma Inc., Sanofi, Eisai Co., Ltd., Merck KGaA, among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL NEGLECTED TROPICAL DISEASE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL NEGLECTED TROPICAL DISEASE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL NEGLECTED TROPICAL DISEASE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.1.1 INCEDENCE OF ANTHRAX
5.1.1.1. INCEDENCE OF LEISHMANIAS
5.1.1.2. INCEDENCE OF TRACHOMA
5.1.1.3. INCEDENCE OF ONCHOCERIASIS
5.1.1.4. INCEDENCE OF LYMPHATIC FILARIASIS
5.1.1.5. INCEDENCE OF SOIL TRANSMITTED HELMITHS
5.1.1.6. INCEDENCE OF SCHISTOSOMIASIS
5.1.2 INCEDENCE OF ANTHRAX TREATED BY SURGERY
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH PATHOLOGIST
6.8 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE I CANDIDATE
9.5 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, BY TYPE
11.1 OVERVIEW
11.2 LEISHMANIASIS
11.2.1 PENTAVALENT ANTIMONIALS
11.2.1.1. SODIUM STIBOGLUCONATE
11.2.1.1.1. MARKET VALUE (USD MN)
11.2.1.1.2. MARKET VOLUME (SU)
11.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.2. MEGLUMINE ANTIMONIATE
11.2.1.2.1. MARKET VALUE (USD MN)
11.2.1.2.2. MARKET VOLUME (SU)
11.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.2 AMPHOTERICIN B
11.2.2.1. MARKET VALUE (USD MN)
11.2.2.2. MARKET VOLUME (SU)
11.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.3 MEGLUMINE ANTIMONATE
11.2.3.1. MARKET VALUE (USD MN)
11.2.3.2. MARKET VOLUME (SU)
11.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.4 KETOCONAZOLE
11.2.4.1. MARKET VALUE (USD MN)
11.2.4.2. MARKET VOLUME (SU)
11.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.5 FLUCONAZOLE
11.2.5.1. MARKET VALUE (USD MN)
11.2.5.2. MARKET VOLUME (SU)
11.2.5.3. AVERAGE SELLING PRICE (USD)
11.2.6 ITRACONAZOLE
11.2.6.1. MARKET VALUE (USD MN)
11.2.6.2. MARKET VOLUME (SU)
11.2.6.3. AVERAGE SELLING PRICE (USD)
11.2.7 OTHERS
11.3 TRACHOMA, BY TREATMENT
11.3.1 AZITHROMYCIN
11.3.1.1. MARKET VALUE (USD MN)
11.3.1.2. MARKET VOLUME (SU)
11.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.2 TETRACYCLINE EYE OINTMENT
11.3.2.1. MARKET VALUE (USD MN)
11.3.2.2. MARKET VOLUME (SU)
11.3.2.3. AVERAGE SELLING PRICE (USD)
11.3.3 OTHERS
11.4 ONCHOCERCIAIS, BY TREATMENT
11.4.1 IVERMECTIN
11.4.1.1. MARKET VALUE (USD MN)
11.4.1.2. MARKET VOLUME (SU)
11.4.1.3. AVERAGE SELLING PRICE (USD)
11.4.2 DOXYCYCLINE
11.4.2.1. MARKET VALUE (USD MN)
11.4.2.2. MARKET VOLUME (SU)
11.4.2.3. AVERAGE SELLING PRICE (USD)
11.4.3 OTHERS
11.5 LYMPHATIC FILARIASIS, BY TREATMENT
11.5.1 ALBENDAZOLE
11.5.1.1. MARKET VALUE (USD MN)
11.5.1.2. MARKET VOLUME (SU)
11.5.1.3. AVERAGE SELLING PRICE (USD)
11.5.2 DIETHYLCARBAZINE
11.5.2.1. MARKET VALUE (USD MN)
11.5.2.2. MARKET VOLUME (SU)
11.5.2.3. AVERAGE SELLING PRICE (USD)
11.5.3 IVERMECTIN
11.5.3.1. MARKET VALUE (USD MN)
11.5.3.2. MARKET VOLUME (SU)
11.5.3.3. AVERAGE SELLING PRICE (USD)
11.5.4 OTHERS
11.6 SOIL TRANSMITTED HELMINTHS, BY TREATMENT
11.6.1 ALBENDAZOLE
11.6.1.1. MARKET VALUE (USD MN)
11.6.1.2. MARKET VOLUME (SU)
11.6.1.3. AVERAGE SELLING PRICE (USD)
11.6.2 MEBENDAZOLE
11.6.2.1. MARKET VALUE (USD MN)
11.6.2.2. MARKET VOLUME (SU)
11.6.2.3. AVERAGE SELLING PRICE (USD)
11.6.3 IVERMECTIN
11.6.3.1. MARKET VALUE (USD MN)
11.6.3.2. MARKET VOLUME (SU)
11.6.3.3. AVERAGE SELLING PRICE (USD)
11.6.4 OTHERS
11.7 SCHISTOSOMIASIS, BY TREATMENT
11.7.1 PRAZIQUANTEL
11.7.1.1. MARKET VALUE (USD MN)
11.7.1.2. MARKET VOLUME (SU)
11.7.1.3. AVERAGE SELLING PRICE (USD)
11.7.2 OTHERS
11.8 OTHERS
12 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.3 ORAL
12.4 OTHERS
13 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 CLINICS
13.4 ACADEMIC AND RESEARCH INSTITUTES
13.5 OTHERS
14 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 OTHERS
15 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, BY GEOGRAPHY
15.1 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.1.1. U.S. NEGLECTED TROPICAL DISEASE MARKET, BY TYPE
15.2.1.2. U.S. NEGLECTED TROPICAL DISEASE MARKET, BY ROUTE OF ADMINISTRATION
15.2.1.3. U.S. NEGLECTED TROPICAL DISEASE MARKET, BY END USER
15.2.1.4. U.S. NEGLECTED TROPICAL DISEASE MARKET, BY DISTRIBUTION CHANNEL
15.2.2 CANADA
15.2.3 MEXICO
15.2.4 DOMINICAN REPUBLIC
15.2.5 JAMAICA
15.2.6 PANAMA
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K.
15.3.4 HUNGARY
15.3.5 LITHUANIA
15.3.6 AUSTRIA
15.3.7 IRELAND
15.3.8 NORWAY
15.3.9 POLAND
15.3.10 ITALY
15.3.11 SPAIN
15.3.12 RUSSIA
15.3.13 TURKEY
15.3.14 NETHERLANDS
15.3.15 SWITZERLAND
15.3.16 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 TAIWAN
15.4.4 SOUTH KOREA
15.4.5 INDIA
15.4.6 AUSTRALIA
15.4.7 SINGAPORE
15.4.8 THAILAND
15.4.9 MALAYSIA
15.4.10 INDONESIA
15.4.11 PHILIPPINES
15.4.12 VIETNAM
15.4.13 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 BRAZIL
15.5.2 ECUADOR
15.5.3 CHILE
15.5.4 COLOMBIA
15.5.5 VENEZUELA
15.5.6 ARGENTINA
15.5.7 PERU
15.5.8 CURAÇAO
15.5.9 PARAGUAY
15.5.10 URUGUAY
15.5.11 TRINIDAD AND TOBAGO
15.5.12 REST OF SOUTH AMERICA
15.6 MIDDLE EAST AND AFRICA
15.6.1 SOUTH AFRICA
15.6.2 SAUDI ARABIA
15.6.3 UAE
15.6.4 EGYPT
15.6.5 KUWAIT
15.6.6 ISRAEL
15.6.7 BOLIVIA
15.6.8 REST OF MIDDLE EAST AND AFRICA
15.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL NEGLECTED TROPICAL DISEASE MARKET, COMPANY PROFILE
18.1 EMERGENT BIOSOLUTIONS
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 GSK
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 ELUSYS THERAPEUTICS
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 BAYER
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 PFIZER
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 ALTIMMUNE INC
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 PORTON BIOPHARMA
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 GILEAD SCIENCES
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 CELGENE CORPORATION
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 SUN PHARMACEUTICALS
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 CADILA HEALTHCARE
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 TAKEDA PHARMACEUTICALS
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 BRISTOL MEYERS SQUIBB
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 TEVA PHARMACEUTICALS
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 JOHNSON & JOHNSON
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 ELI LILLY
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 SANOFI
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 BOEHRINGER INGELHEIM
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 ASTRAZENCA
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 CIPLA, INC
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 F-HOFFMANN LA ROCHE
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 ABBVIE
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 NOVARTIS AG
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 AMGEN
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 MERCK & CO, INC
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
18.26 SHIRE PHARMACEUTICALS
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPMENTS
18.27 BAUSCH HEALTH
18.27.1 COMPANY OVERVIEW
18.27.2 REVENUE ANALYSIS
18.27.3 GEOGRAPHIC PRESENCE
18.27.4 PRODUCT PORTFOLIO
18.27.5 RECENT DEVELOPMENTS
18.28 EISAI CO.,
18.28.1 COMPANY OVERVIEW
18.28.2 REVENUE ANALYSIS
18.28.3 GEOGRAPHIC PRESENCE
18.28.4 PRODUCT PORTFOLIO
18.28.5 RECENT DEVELOPMENTS
18.29 GRIFOLS
18.29.1 COMPANY OVERVIEW
18.29.2 REVENUE ANALYSIS
18.29.3 GEOGRAPHIC PRESENCE
18.29.4 PRODUCT PORTFOLIO
18.29.5 RECENT DEVELOPMENTS
18.3 ALEXION PHARMACEUTICALS
18.30.1 COMPANY OVERVIEW
18.30.2 REVENUE ANALYSIS
18.30.3 GEOGRAPHIC PRESENCE
18.30.4 PRODUCT PORTFOLIO
18.30.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
